NINEMakhmudova L.I.
Khojiev B.B.
10.5281/zenodo.20511832
Annotatsiya
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder
worldwide, strongly associated with obesity, insulin resistance, and metabolic
syndrome. The disease ranges from simple steatosis to nonalcoholic steatohepatitis
(NASH), fibrosis, and cirrhosis. This study evaluates clinical, laboratory, and
instrumental findings in patients with NAFLD and assesses metabolic risk factors
associated with disease severity.
Kalit so'zlar:
NAFLD, insulin resistance, HOMA-IR, steatosis, metabolic syndrome, fibrosis
Foydalanilgan adabiyotlar
1. Younossi ZM et al. Global epidemiology of NAFLD. Hepatology. 2020.
2. Eslam M, Newsome PN. MAFLD concept and metabolic dysfunction. J Hepatol.
2020.
3. Loomba R, Adams LA. Advances in NAFLD diagnosis. Nat Rev Gastroenterol Hepatol.
2021.
4. Byrne CD, Targher G. NAFLD as multisystem disease. J Hepatol. 2018–2021.
5. Tilg H, Effenberger M. Insulin resistance in NAFLD. Hepatology. 2020.
6. Angulo P et al. Natural history of NAFLD. Gastroenterology. 2019.
7. European Association for the Study of the Liver (EASL) guidelines. 2021.
